Quiet Therapeutics Ltd.

Quiet Therapeutics Ltd. specializes in the sale and leasing of premium domain names, providing secure and efficient solutions for clients seeking to establish their digital identity. Founded in 2009, Quiet Therapeutics Ltd. focuses on domain sales and leasing.

The company secured a Series A funding round in April 2015, raising USD 12 mn from Jerusalem Global Ventures. The company's headquarters are located in Israel, and it has completed 2 deals since its inception. Notably, the founder has a history of involvement in previous ventures, enhancing their expertise in the domain market. Quiet Therapeutics Ltd.

specializes in the sale and leasing of premium domain names, offering a streamlined and secure purchasing process for clients in need of a digital identity. The company’s core offerings include a one-time purchase option for domains, a lease-to-own model allowing for monthly payments, and an opportunity for potential buyers to submit offers. These services cater to a diverse clientele ranging from small startups to established corporations across various industries seeking to enhance their online presence. The company operates in multiple geographical markets, focusing on regions with robust digital economies, including North America, Europe, and parts of Asia.

Each transaction is designed to provide a hassle-free experience, ensuring secure payments and transaction support for customers, thereby addressing the common challenges associated with domain acquisition. The revenue model for Quiet Therapeutics Ltd. is primarily driven by domain sales and leasing arrangements with customers. The company generates income through direct transactions, where clients can either purchase a domain outright for a set price or opt for the lease-to-own structure, which typically involves monthly payments.

For example, a customer interested in acquiring the domain quietx. com could choose to pay the full price of USD 49,850 or select the lease option at USD 1,081 per month, allowing flexibility based on their financial strategy. The transaction structure is set up to accommodate both business-to-consumer (B2C) and business-to-business (B2B) relationships, providing a versatile platform for different types of clients. As each domain is marketed as a premium verified offering, the pricing reflects the perceived value and demand within the digital marketplace.

Future growth plans for Quiet Therapeutics Ltd. include the development of new premium domain offerings and the exploration of additional leasing models. The company aims to enhance its presence in emerging markets in Asia and South America by 2025, leveraging the recent Series A funding of USD 12 mn raised in April 2015 from Jerusalem Global Ventures to support these initiatives. This funding will facilitate expansion into targeted regions with growing digital economies and the launch of innovative product offerings.